

Estimated global incidence of Japanese encephalitis: a systematic review

Grant L Campbell,^a Susan L Hills,^b Marc Fischer,^b Julie A Jacobson,^c Charles H Hoke,^d Joachim M Hombach,^e Anthony A Marfin,^f Tom Solomon,^g Theodore F Tsai,^h Vivien D Tsuiⁱ & Amy S Ginsburgⁱ

Objective To update the estimated global incidence of Japanese encephalitis (JE) using recent data for the purpose of guiding prevention and control efforts.

Methods Thirty-two areas endemic for JE in 24 Asian and Western Pacific countries were sorted into 10 incidence groups on the basis of published data and expert opinion. Population-based surveillance studies using laboratory-confirmed cases were sought for each incidence group by a computerized search of the scientific literature. When no eligible studies existed for a particular incidence group, incidence data were extrapolated from related groups.

Findings A total of 12 eligible studies representing 7 of 10 incidence groups in 24 JE-endemic countries were identified. Approximately 67 900 JE cases typically occur annually (overall incidence: 1.8 per 100 000), of which only about 10% are reported to the World Health Organization. Approximately 33 900 (50%) of these cases occur in China (excluding Taiwan) and approximately 51 000 (75%) occur in children aged 0–14 years (incidence: 5.4 per 100 000). Approximately 55 000 (81%) cases occur in areas with well established or developing JE vaccination programmes, while approximately 12 900 (19%) occur in areas with minimal or no JE vaccination programmes.

Conclusion Recent data allowed us to refine the estimate of the global incidence of JE, which remains substantial despite improvements in vaccination coverage. More and better incidence studies in selected countries, particularly China and India, are needed to further refine these estimates.

Abstracts in عربي, 中文, Français, Русский and Español at the end of each article.

Introduction

Japanese encephalitis (JE) is among the most important viral encephalitides in Asia, especially in rural and suburban areas where rice culture and pig farming coexist.^{1–3} It has also occurred rarely and sporadically in northern Australia and parts of the Western Pacific.^{4–6} JE is due to infection with the JE virus (JEV), a mosquito-borne flavivirus. The main JEV transmission cycle involves *Culex tritaeniorhynchus* mosquitoes and similar species that lay eggs in rice paddies and other open water sources, with pigs and aquatic birds as principal vertebrate amplifying hosts.^{1,2,7} Humans are generally thought to be dead-end JEV hosts, i.e. they seldom develop enough viremia to infect feeding mosquitoes. Fewer than 1% of human JEV infections result in JE. Approximately 20–30% of JE cases are fatal and 30–50% of survivors have significant neurologic sequelae.⁸ JE is primarily a disease of children and most adults in endemic countries have natural immunity after childhood infection, but all age groups are affected. In most temperate areas of Asia, JEV is transmitted mainly during the warm season, when large epidemics can occur. In the tropics and subtropics, transmission can occur year-round but often intensifies during the rainy season.^{1–3}

The global incidence of JE is unknown because the intensity and quality of JE surveillance and the availability of diagnostic laboratory testing vary throughout the world. Countries that have implemented high-quality childhood JE vaccination programmes have seen a dramatic decline in JE incidence. Although JE is reportable to the World Health Organization (WHO) by its Member States, reporting is highly variable and incomplete. In the late 1980s, Burke and Leake estimated that 50 000 new cases of JE occurred annually among the 2.4 billion people living in the 16 Asian countries considered endemic at the time (approximate overall annual incidence: 2 per 100 000).² In the intervening two decades, despite major population growth, urbanization, changes in agricultural practices and increased use of the JE vaccine in many countries, this figure has been widely quoted, including very recently.^{9–13} In 2000, assuming an annual, age-group-specific incidence of 25 cases per 100 000, Tsai estimated that in the absence of vaccination 175 000 cases of JE would occur annually among Asian children aged 0–14 years living in rural areas.¹⁴ The current study used more recent, published, local or national incidence estimates and current population data to produce an updated estimate of the annual global incidence of JE.

^a Ross River Consulting, LaPorte, United States of America (USA).

^b Centers for Disease Control and Prevention, Fort Collins, USA.

^c Bill & Melinda Gates Foundation, Seattle, USA.

^d Pharmaceutical Systems Project Management Office, US Army Medical Material Development Activity, Fort Detrick, USA.

^e Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland.

^f Washington State Department of Health, Communicable Disease Epidemiology, Shoreline, USA.

^g Institute of Infection and Global Health, University of Liverpool, Liverpool, England.

^h Scientific Affairs, Novartis Vaccines, Cambridge, USA.

ⁱ Program for Appropriate Technology in Health (PATH), PO Box 900922, Seattle, WA, 98109, USA.

Correspondence to Amy S Ginsburg (e-mail: AGinsburg@path.org).

(Submitted: 9 December 2010 – Revised version received: 17 June 2011 – Accepted: 10 July 2011 – Published online: 3 August 2011)

Methods

We approximated the JE-affected territory of each of the 24 countries endemic for JE using a recent update¹⁵ of an earlier approximation by Tsai¹⁶ with some modifications (Table 1, available at: <http://www.who.int/bulletin/volumes/89/10/10-085233>). Based on these same approximations,^{15,16} we then stratified the JE-affected territory of some countries (e.g. China excluding Taiwan, India and Nepal) into two or more incidence strata. Because suitable studies of JE incidence were not available for every endemic country or incidence stratum, we sorted JE-endemic countries and incidence strata into 10 incidence groups (A, B, C1, C2 and D through I) based primarily on geographic proximity, ecologic similarity, vaccine programme similarity. Table 1 briefly describes the status of each endemic country's JE vaccination programme as of 2009, according to recent publications and unpublished sources.^{8,17–20}

Incidence data

We identified studies that contained potentially useful data on the incidence of JE in Asia in a manner similar to the one used in a recent study of global typhoid fever incidence.²¹ Whenever possible, this review followed the relevant guidelines for Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).²² The review process is described as follows and no protocol is available. We conducted a MedLine search of papers in any language published between 1985 (arbitrarily chosen to emphasize recent data) and April 2010. We used the following search strategy and keywords: Japanese encephalitis *and* (incidence *or* prevalence *or* public health *or* surveillance *or* distribution *or* epidemiology). An initial set of 1374 unique citations was downloaded into a computerized database. The lead author then culled the set to approximately 255 citations by scanning titles and abstracts (if available) and discarding references that did not involve JE surveillance or epidemiology in humans (e.g. studies focused on non-human vertebrates or on entomology, molecular biology or virology). The lead author also obtained a full-text copy of each available reference for review and further culled the list to approximately 75 references by selecting only those that contained explicit human JE incidence data or data that could be used to calculate

incidence. Additional references were sought from these papers' reference lists and from the collections of the authors (including several papers recently submitted or "in press"), and this yielded a total of 80 references of interest. Each of these papers (or the English translation of five Chinese-language papers) was then carefully reviewed by at least two authors to further cull the list, resulting in a final group of 12 studies that provided original, recent population-based and largely laboratory-confirmed incidence data (or hospital-based incidence data in a defined population).^{13,20,23–32} These 12 studies consisted of one study each from Bangladesh, Cambodia, Indonesia, Malaysia and Thailand, two from China (excluding Taiwan) two from Japan and three from Nepal. They represented all but three (B, E and I) of the 10 incidence groups (Table 1). Fig. 1 shows the approximate locations of the study sites in each primary reference. Point estimates of the annual JE incidence in each primary reference are shown as cases per 100 000 persons (Table 2, <http://www.who.int/bulletin/volumes/89/10/10-085233>).

We used an Excel spreadsheet for all calculations in this study.


Population data

For each endemic country, we obtained the total population and that of the approximate JE-affected area from the country's official web site (as identified through www.GeoHive.com). We used the most recent census data (1998–2011) or official inter-census estimates (2000–2010) and dichotomized age as follows: children, aged 0–14 years; adults, aged ≥ 15 years (Table 1). For each country, the estimated total population aged 0–14 years was based on percentages for 2010 obtained from the United Nations³³ (for Taiwan, China, the percentage was obtained from *The world factbook*³⁴). Because a concise source of such percentages for JE-endemic administrative divisions and subdivisions of countries was not available, we assumed that the age distribution within each country was homogeneous.

Assumptions by incidence group

In unvaccinated populations in endemic areas, JE is largely a paediatric disease and most people have acquired active

Fig. 1. Primary reference study area(s)



^a Mountain and hill (non-Terai) districts only

immunity by adulthood. Conversely, in areas with long-standing, high-quality childhood vaccination programmes, JE is usually a rare disease of non-immune adults, especially the elderly. A transitional phase in which the incidence of JE in children and adults is about the same can also occur.³ Because many of our primary references provided point estimates of JE incidence for all age groups combined or for children only (generally 0–14-year-olds), assumptions about age-specific JE incidence were often necessary. We had to make additional assumptions because of the absence of appropriate primary references for incidence groups B, E and I. We assumed that in some countries with a historically non-homogeneous distribution of JE risk (e.g. plain versus highland areas of Sri Lanka and northern versus southern portions of Thailand), the preferential use of vaccine in areas that were formerly higher-risk has homogenized the risk countrywide. Incidence groups are described in [Table 1](#) and additional group-specific assumptions are summarized as follows:

- *Incidence Group A:* Overall incidence is 0.003 per 100 000; the child (aged ≤ 14 years) to adult (aged > 14 years) case frequency ratio is 7:1 (based on visual inspection of a figure in the report by Arai et al.²³). Because this study²³ and the study by Hashimoto et al.²⁴ overlapped in time and because both were based on national surveillance, a weighted average of their respective results could not be used. Therefore, we used the incidence estimate by Arai et al. in our analysis but included the study by Hashimoto et al. in [Table 2](#) for completeness and as general validation of the results obtained by Arai et al.
- *Incidence Group B:* JE is rare, with an overall incidence of 0.003 per 100 000, i.e. the authors assumed it to be the same as in historically high-incidence areas with long-standing, high-quality vaccination programmes (i.e. Incidence Group A); the child to adult case frequency ratio is 7:1.²³
- *Incidence Group C1:* Overall incidence is 3.3 per 100 000 (weighted average of results from Yin et al.²⁰ and Xufang et al.¹³); the child to adult case frequency ratio is 3:1 (based on the ratio of 156 cases in 0–14-year-olds to 57 cases in persons aged > 14 years among combined residents and non-residents, as reported by Yin et al.²⁰).
- *Incidence Group C2:* Overall incidence is 0.01 per 100 000; the child to adult case frequency ratio is 3:1 (as for Incidence Group C1).
- *Incidence Group D:* Incidence in children aged 12–14 years is the same as in children aged 0–11 years; incidence in children aged 0–14 years is 10.6 per 100 000 (weighted average of results from Touch et al.,²⁵ Kari et al.²⁶ and Hoke et al.²⁷); the child to adult case frequency ratio is 7:1 (based on the ratio of 43 childhood cases to 6 adult cases detected from July 2001 through 2006 by Wong et al.³²).
- *Incidence Group E:* Age-specific incidences in this group are assumed by the authors to be half as high as in incidence group D.
- *Incidence Group F:* Overall incidence is 2.8 per 100 000 (approximate weighted average of results from two studies from Nepal^{28,29}); the child to adult case frequency ratio is 5:4 (based on the ratio of 532 cases in 0–14-year-olds to 419 cases in persons aged > 14 years, as reported by Wierzbza et al.²⁹).
- *Incidence Group G:* Overall incidence is 1.0 per 100 000 (approximate weighted average of results from three studies from Nepal^{28,29,31} and one study from Bangladesh³⁰); the child to adult case frequency ratio is 4:1 (based on the ratio of 73 cases in 0–14-year-olds to 17 cases in persons aged > 14 years, per the table in the report by Bhattachan and colleagues³¹).
- *Incidence Group H:* Overall incidence is 1.5 per 100 000 (based on 49 cases per 600 000 persons over a 5.5-year period in the study by Wong et al.); incidence in children aged 12–14 years is the same as in children aged 0–11 years; the child to adult case frequency ratio is 7:1.³²
- *Incidence Group I:* Overall incidence is 3.3 per 100 000 (based on the average annual incidence of 6.5 per 100 000 in nearby Taiwan (China) during the immediate pre-vaccination era [1965–1967],³⁵ reduced by 50% following a national mass-vaccination campaign among children in 2009); the child to adult case frequency ratio is 7:1.³²

Results

Based on the assumptions noted above, we estimated that approximately 67 900 JE cases typically occur annually in the 24 JE-endemic countries, for an incidence of 1.8 per 100 000 overall ([Table 3](#)). Approximately 33 900 (50%) of these cases occur in China (excluding Taiwan) and approximately 55 000 (81%) occur in areas with well established or developing JE vaccination programmes, while approximately 12 900 (19%) occur in areas with minimal or no JE vaccination programmes. Approximately 51 000 (75%) of these cases occur in children aged 0–14 years, which gives an estimated overall annual incidence of 5.4 per 100 000 in this age group.

Discussion

In the pre-JE-vaccination era, tens of thousands of JE cases were often reported annually in Asia. During 1965–1975, more than 1 million cases were reported in China alone.¹ In Japan, the Republic of Korea and Taiwan (China) the introduction of routine childhood vaccination programmes against JE beginning 40 to 50 years ago, combined with increased urbanization and evolving agricultural practices, resulted in the virtual elimination of JE, despite continued enzootic JEV transmission.^{2,14} Other Asian countries were slower to implement childhood JE vaccination programmes largely because of expenses and difficult logistics. Some of these countries now have well developed vaccination programmes, others have less developed programmes, and others still have no programmes at all.^{8,17,19}

During 2006–2009, JE-endemic countries reported 27 059 cases of JE (annual range: 4502–9459; average: 6765) to WHO. Fully 86% of these (23 176 cases; average: 5794 cases per year) were reported from China and India; 16 countries reported a total of 3883 cases (annual average: 971); and 5 countries reported no cases.³⁶ While these data almost certainly include some non-JE cases that were clinically misclassified without the benefit of laboratory confirmation, they almost certainly also represent significant under-reporting of true cases.^{1,14} The results of the current study suggest that the actual incidence of JE is nearly 10 times higher than reflected in recent reports to WHO. While we estimated that approximately 81% of JE cases presently occur in areas with well

Table 3. Estimated annual incidence and case frequency of Japanese encephalitis (JE) by incidence group and age stratum^a

IG	Description	Countries/regions	0–14 years of age			≥ 15 years of age			All ages			
			Endemic area(s) population (millions)	Incidence ^b	Frequency	Endemic area(s) population (millions)	Incidence ^b	Frequency	Endemic area(s) population (millions)	Incidence ^b	Frequency	Percentage of total ^c
A	Historically high-incidence areas with long-standing, high-quality vaccination programmes	Japan, Republic of Korea, China (Taiwan)	28.5	0.003	1	170.0	0.003	5	198.5	0.003	6	<0.1
B	Extremely low-incidence areas; rare human cases; minimal or no vaccination programmes	Australia, India (lowest-incidence stratum), Pakistan, Russian Federation, Singapore	28.0	0.001	0	61.5	0.004	2	89.5	0.003	2	<0.1
C1	Historically high-incidence areas with expanding vaccination programmes	China (higher-incidence stratum)	200.0	12.7	25387	825.7	1.0	8462	1025.7	3.3	33849	49.9
C2	Historically medium-incidence areas with expanding vaccination programme	China (lower-incidence stratum)	53.9	0.04	21	222.7	0.003	7	276.6	0.01	28	<0.1
D	High-incidence areas with nascent or no vaccination programmes	Cambodia, Indonesia (higher-incidence stratum), Lao People's Democratic Republic, Malaysia (Borneo except Sarawak), Myanmar, Philippines, Timor-Leste	65.4	10.6	6927	146.4	0.7	990	211.8	3.7	7917	11.7

IG	Description	0–14 years of age			≥ 15 years of age			All ages			
		Endemic area(s) population (millions)	Incidence ^b	Frequency	Endemic area(s) population (millions)	Incidence ^b	Frequency	Endemic area(s) population (millions)	Incidence ^b	Frequency	Percentage of total ^c
E	Medium-incidence areas with no vaccination programmes	58.9	5.3	3122	154.6	0.34	523	213.5	1.7	3645	5.4
F	Historically high-incidence areas with expanding vaccination programmes	135.7	5.1	6861	305.4	1.8	5489	441.1	2.8	12350	18.2
G	Low-incidence areas with minimal or no vaccination programmes	43.0	2.5	1086	92.8	0.3	272	135.8	1.0	1358	2.0
H	Historically medium-to-high-incidence areas with expanding vaccination programmes	151.1	4.7	7063	387.0	0.3	1009	538.1	1.5	8072	11.9
I	Historically medium-to-high-incidence area with expanding vaccination programme	4.6	12.6	586	15.7	0.5	84	20.3	3.3	670	1.0
Total (JE-endemic areas only)		769.2	6.6	51054	2381.7	0.7	16843	3150.9	2.2	67897	100
Overall incidence (endemic + non-endemic areas)^b		–	5.4	–	–	0.6	–	–	1.8	–	–

IG, incidence group.

^a Total population (endemic + non-endemic areas) aged 0–14 years is 1000.9 million; aged ≥ 15 years, 2692.7 million; and combined, 3693.6 million (country-specific data not shown).^b Per 100 000.^c Total frequency divided by 67 897 times 100. Note: See text for assumptions.

established or developing JE vaccination programmes, this probably reflects the epidemiological distribution of JE, since vaccination programmes are more likely to exist in areas with the highest risk of JEV transmission. It may also reflect better surveillance and case-reporting in such areas. Vaccination programmes in many of these areas should be expanded and strengthened. Endemic countries without programmes or with programmes in early development should be fully supported in their efforts to implement and strengthen JE vaccination programmes.

Because we studied JE incidence, not mortality or morbidity (e.g. in terms of disability-adjusted life years [DALY]), we did not attempt to estimate the global burden of JE.^{37,38} Nevertheless, our results could contribute to efforts to refine estimates of this burden. Based on an earlier estimated frequency of 44 000 new JE cases per year, including 14 000 deaths (32%) and 24 000 cases with sequelae (55%, or 71% of survivors), and an average disability weight of 0.616, Mathers et al. estimated the global burden of JE to be 709 000 DALY (by comparison, the estimated global burden of acute malaria was 46 000 000 DALY).³⁷ If we assume a case fatality rate of 20–30% and long-term neuropsychological morbidity among 30–50% of survivors,⁸ the results of the current study similarly suggest that approximately 13 600 to 20 400 acutely fatal JE cases occur and that 14 300 to 27 200 JE survivors develop long-term neuropsychological sequelae each year. Although several studies characterizing long-term outcomes in JE survivors have been published,^{39–42} additional studies are needed to allow for refined estimates of the global burden of JE.

The methods we used in the current study resembled the methods that have been employed to estimate the global incidence of other infectious diseases, including typhoid fever, *Haemophilus influenzae* type b disease and streptococcal disease.^{21,43,44} Our study is therefore subject to many of the same limitations. First, we derived estimates from sparse data of variable quality, with some notable exceptions (e.g. data from Japan). Furthermore, useful data were lacking from several important countries or parts of countries.

The absence of data from India is particularly worrisome because the country has a very large population and several diverse JE-endemic regions. Although we did not feel that a formal sensitivity analysis was essential to enable us to appropriately interpret our results, these results would obviously be highly sensitive to relatively small changes in some input data, especially for China and India, which together contain approximately two thirds of the world's population at risk for JE. This is particularly true for Incidence Group C1 (the higher-incidence stratum of China), which accounted for half of our estimated global total of annual JE cases, and, to a lesser extent, for incidence groups D, F and H (much of India and south-eastern Asia). In contrast, our results would be far less sensitive to changes in input data for incidence groups A, B, C2 and I. Another limitation of our approach is that some of the 12 key references for JE incidence involved hospital-based surveillance in imperfectly defined catchment areas. Such studies tend to underestimate true incidence because they depend on all true cases being hospitalized (as opposed to being treated as outpatients) and within their residential catchment area. Other studies relied on an incomplete network of sentinel hospitals and are similarly subject to an underreporting bias, although such a bias is not readily quantifiable. The following are also potential sources of error that are difficult to quantify: (i) a lack of standardized laboratory testing methods (e.g. the use of various commercially available or in-house test kits for the detection of anti-JEV immunoglobulin M antibody); (ii) incomplete collection of clinical samples (e.g. failure to collect and test both acute- and convalescent-phase samples in all suspected cases, resulting in some degree of underdiagnosis); and (iii) the co-circulation of other cross-reactive flaviviruses (especially dengue viruses) in some JE-endemic areas.

We did not attempt to distinguish between urban and rural incidence because few, if any, of the studies on which our results were based broke down incidence in this way. They involved surveillance in whole countries or in areas that included a mix of urban and rural populations. Nevertheless, the risk of JE continues to be

strongly associated with exposure in rural and, to a lesser extent, suburban areas.³ Another limitation of our approach is that JE is an ecologically complex epidemic as well as endemic disease and therefore does not exist in a steady-state, even when incidence is reduced by means of increased vaccine usage. Thus, to state that a set number of new JE cases occurs globally each year (e.g. 50 000, 67 900 or 175 000) is overly simplistic, however convenient it may be for some purposes, because the situation is clearly more dynamic. It was recently discovered, for example, that the JEV is circulating in Tibet (China), formerly believed to be non-endemic.⁴⁵ More accurate estimates of the global incidence of JE, including its natural fluctuations over time, will await the development of better surveillance and laboratory capability throughout the endemic region, as well as the publication of additional population-based surveillance studies of laboratory-confirmed cases. To this end, agencies funding vaccine programmes should consider concurrently funding well designed, population-based surveillance studies of laboratory-confirmed cases, particularly in JE-endemic countries for which no reliable incidence data currently exist. ■

Acknowledgements

The authors thank Sybil Barney, James Cheyne, Laure Dumolard, Lauren Gazley, Erin Kester, Megan Le, Jennifer Lehman and Ginger Topel for administrative support; Pritu Dhalara Raj, Shankar Ghosh and Mong How Ooi for helpful consultations and discussions; Repon Paul and Zundong Yin for sharing “in press” manuscripts; and Tang Yi for graciously providing translations of selected articles published in Chinese.

Funding: This study was funded by the Program for Appropriate Technology in Health (PATH).

Competing interests: Theodore Tsai is a full-time employee of Novartis Vaccines. The views expressed in this publication are those of the authors alone and do not necessarily represent the decisions, policy, or views of the Centers for Disease Control and Prevention.

ملخص

معدل الانتشار التقديري العالمي لالتهاب الدماغ الياباني: مراجعة منهجية

(معدل الانتشار الإجمالي: 1.8 لكل 100000)، ولا يُبلغ منها إلى منظمة الصحة العالمية إلا 10% فقط. وتقع حوالي 33900 (50%) من هذه الحالات في الصين (باستثناء تايوان، الصين) وتقع حوالي 51000 حالة (75%) في الأطفال في عمر 0-14 سنة (معدل الوقوع: 5.4 لكل 100000). وحوالي 55000 حالة (81%) تقع في مناطق يستقر فيها برامج التمنيع ضد التهاب الدماغ الياباني أو يجري تطوير البرامج فيها، بينما تقع حوالي 12900 حالة (19%) في مناطق لا يوجد فيها برامج التمنيع أو أنها توجد على نطاق محدود. الاستنتاج تتيح المعطيات الحديثة لنا تصحيح معدل الانتشار التقديري العالمي لالتهاب الدماغ الياباني، والذي مازال منتشرًا على نطاق واسع بالرغم من التحسن الذي شهدته برامج التمنيع. وهناك حاجة إلى مزيد من دراسات أفضل حول معدل الانتشار في بلاد منتقاة، ولاسيما الهند والصين، من أجل تصحيح هذه التقديرات.

الغرض تحديث معدل الانتشار التقديري العالمي لالتهاب الدماغ الياباني باستخدام المعطيات الحديثة بهدف توجيه جهود الوقاية والمكافحة. الطريقة جري ترتيب اثنين وثلاثين منطقة وبائية ينتشر فيها التهاب الدماغ الياباني، في 24 بلدًا آسيويًا وفي غرب المحيط الهادي، إلى 10 مجموعات وفقًا لمعدل الانتشار على أساس المعطيات المنشورة ورأي الخبراء. وقد بُحِثَ عن الدراسات الاستقصائية السكانية التي استخدمت حالات مؤكدة مختبريًا عن طريق البحث الحاسوبي في النشرات العلمية لكل مجموعة من مجموعات معدل الانتشار. وإذا لم توجد دراسات عن معدل الانتشار تصلح لمجموعة محددة من مجموعات معدل الانتشار، يجري استيفاء معطيات الانتشار من المجموعات ذات العلاقة. النتائج تم إجمالاً تحديد 12 دراسة تصلح للإدراج في البحث، وقد مثلت 7 إلى 10 مجموعات وفقًا لمعدل الانتشار في 24 بلدًا متوطنًا فيها التهاب الدماغ الياباني. وتبين أنه تقع سنويًا 67900 حالة نموذجية من التهاب الدماغ الياباني

الخلاصة

التهاب الدماغ الياباني: تقييم الانتشار العالمي: استعراض منهجي

الهدف يهدف إلى تحديث معدل الانتشار التقديري العالمي لالتهاب الدماغ الياباني (JE) باستخدام أحدث البيانات، وذلك لتوفير توجيهات للوقاية والتحكم.

الطريقة استنادًا إلى البيانات المنشورة وآراء الخبراء، تم تصنيف 24 منطقة وبائية منتشرة في آسيا والمحيط الهادئ إلى 10 مجموعات وفقًا لمعدل الانتشار. تم إجراء بحث عن الدراسات الاستقصائية السكانية التي استخدمت حالات مؤكدة مختبريًا عن طريق البحث الحاسوبي في النشرات العلمية لكل مجموعة من مجموعات معدل الانتشار. وإذا لم توجد دراسات عن معدل الانتشار تصلح لمجموعة محددة من مجموعات معدل الانتشار، جرى استيفاء معطيات الانتشار من المجموعات ذات العلاقة.

النتائج تم إجمالاً تحديد 12 دراسة تصلح للإدراج في البحث، وقد مثلت 7 إلى 10 مجموعات وفقًا لمعدل الانتشار في 24 بلدًا متوطنًا فيها التهاب الدماغ الياباني. وتبين أنه تقع سنويًا 67900 حالة نموذجية من التهاب الدماغ الياباني

التهاب الدماغ الياباني. وتبين أنه تقع سنويًا 67900 حالة نموذجية من التهاب الدماغ الياباني

التهاب الدماغ الياباني. وتبين أنه تقع سنويًا 67900 حالة نموذجية من التهاب الدماغ الياباني

Résumé

Estimation de l'incidence mondiale de l'encéphalite japonaise: une évaluation systématique

Objectif Mettre à jour l'estimation de l'incidence mondiale de l'encéphalite japonaise (EJ) à l'aide des données récentes afin de guider les efforts de prévention et de contrôle.

Méthodes Trente-deux régions endémiques de l'EJ dans 24 pays de l'Asie et du Pacifique occidental ont été classées en 10 groupes d'incidence sur la base des données publiées et d'expertises. Des études de surveillance basées sur la population, utilisant des cas confirmés en laboratoire, ont été investiguées pour chaque groupe d'incidence par une recherche informatisée de documentation scientifique. Lorsqu'aucune étude éligible n'existait pour un groupe d'incidence particulier, les données d'incidence étaient extrapolées à partir des groupes associés.

Résultats Un total de 12 études éligibles, représentant 7 des 10 groupes d'incidence dans 24 pays endémiques de l'EJ, a été identifié. Environ 67 900 cas d'EJ sont enregistrés chaque année (incidence totale: 1,8 pour 100 000), dont seulement 10% environ sont

signalés à l'Organisation mondiale de la Santé. Environ 33 900 (50%) de ces cas apparaissent en Chine (à l'exclusion de Taïwan, Chine) et environ 51 000 (75%) cas touchent des enfants de 0 à 14 ans (incidence: 5,4 pour 100 000). Environ 55 000 (81%) cas sont enregistrés dans des régions offrant des programmes de vaccination de l'EJ en voie de développement ou bien établis, alors qu'environ 12 900 (19%) cas apparaissent dans des régions proposant des programmes de vaccination de l'EJ minimum ou inexistantes.

Conclusion Les données récentes nous ont permis d'affiner l'estimation de l'incidence mondiale de l'EJ, qui reste importante malgré les améliorations apportées par la couverture de la vaccination. Des études de l'incidence plus nombreuses et plus précises dans des pays sélectionnés, en particulier la Chine et l'Inde, sont nécessaires pour affiner davantage ces estimations.

Резюме

Оценка заболеваемости японским энцефалитом в мире: систематическое исследование

Цель Используя новейшие данные, внести изменения в оценку заболеваемости японским энцефалитом (ЯЭ) в целях руководства мероприятиями по профилактике этого заболевания и борьбе с ним.

Методы Тридцать два района, эндемичных по ЯЭ, в 24 странах Азии и западной части Тихоокеанского региона были разделены по показателю заболеваемости на 10 групп на основе опубликованных данных и мнений экспертов. По каждой группе был проведен компьютеризированный поиск по научной литературе с целью выявления исследований в области эпидемиологического надзора на базе популяций с использованием лабораторно подтвержденных случаев заболевания. В случае отсутствия исследований, соответствующих требованиям поиска, по какой-либо группе заболеваемости данные о заболеваемости экстраполировались на основе показателей родственных групп.

Результаты Всего было выявлено 12 исследований, отвечающих критериям поиска, которые представляли семь из 10 групп заболеваемости в 24 странах, эндемичных по ЯЭ.

Как правило, ежегодно происходит примерно 67 900 случаев заболевания ЯЭ (средняя заболеваемость: 1,8 на 100 тыс. человек населения), из которых только о 10% направляются уведомления во Всемирную организацию здравоохранения. Приблизительно 33 900 (50%) из этих случаев происходят в Китае (кроме Тайваня) и примерно 51 тыс. (75%) – среди детей в возрасте до 14 лет (заболеваемость: 5,4 на 100 тыс. человек населения). Приблизительно 55 тыс. случаев (81%) происходят в районах, в которых постоянно проводятся или начали осуществляться программы вакцинации от ЯЭ, а примерно 12 900 (19%) – в районах, где программы вакцинации от ЯЭ имеют минимальный охват или не проводятся.

Вывод Новейшие данные позволили нам уточнить оценку заболеваемости ЯЭ в мире. Она остается значительной, несмотря на расширение охвата вакцинацией. Для более полного уточнения этих оценок необходимы более широкие и глубокие исследования заболеваемости в некоторых странах, в частности, в Индии и Китае.

Resumen

Incidencia global estimada de la encefalitis japonesa: una revisión sistemática

Objetivo Actualizar la incidencia global estimada de la encefalitis japonesa (EJ) utilizando datos recientes para orientar los esfuerzos de prevención y control.

Métodos En base a los datos publicados y a la opinión de profesionales especializados, treinta y dos áreas endémicas de EJ en 24 países de Asia y el Pacífico Occidental se clasificaron en 10 grupos de incidencia. Mediante una búsqueda informatizada de la literatura científica, se buscaron estudios de vigilancia basados en la población utilizando casos confirmados en laboratorio para cada grupo de incidencia. Cuando no se encontraron estudios aptos para un grupo de incidencia específico, se procedió a la extrapolación de los datos de incidencia de los grupos en cuestión.

Resultados Se identificaron un total de 12 estudios aptos que representaban 7 de los 10 grupos de incidencia en 24 países con EJ endémica. Aproximadamente, al año se solían producir 67 900 casos de

EJ (incidencia global: 1,8 por cada 100 000 habitantes), de los cuales solo el 10% se notificaron a la Organización Mundial de la Salud. De estos casos, aproximadamente 33 900 (el 50%) se producen en China (excluyendo Taiwán, China) y aproximadamente 51 000 (el 75%) se producen en niños con edades comprendidas entre los 0 y los 14 años (incidencia: 5,4 por cada 100 000 habitantes). Aproximadamente 55 000 (el 81%) casos se producen en áreas en las que existen programas de vacunación de EJ oficialmente establecidos o en desarrollo, mientras que aproximadamente 12 900 (el 19%) se producen en áreas con pocos o con ningún programa de vacunación de EJ.

Conclusión Los recientes datos nos permitieron perfeccionar la estimación de incidencia global de la EJ, que sigue siendo importante, a pesar de las mejoras en la cobertura de vacunación. Es necesario disponer de mejores estudios de incidencia en determinados países, específicamente en China y India, para seguir perfeccionando estas estimaciones.

References

- Halstead SB, Jacobson J. Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines*. 5th ed. Philadelphia: Elsevier; 2008. pp. 311-52.
- Burke DS, Leake CJ. Japanese encephalitis. In: Monath TP, editor. *The arboviruses: epidemiology and ecology*, Vol. 3. Boca Raton: CRC Press; 1988. pp. 63-92.
- Fischer M, Lindsey N, Staples JE, Hills S; Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2010;59(RR-1):1-27. PMID:20224546
- Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, Mackenzie JS et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. *Med J Aust* 1996;165:256-60. PMID:8816682
- Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, van den Hurk AF et al. Japanese encephalitis in north Queensland, Australia, 1998. *Med J Aust* 1999;170:533-6. PMID:10397044
- Paul WS, Moore PS, Karabatsos N, Flood SP, Yamada S, Jackson T et al. Outbreak of Japanese encephalitis on the island of Saipan, 1990. *J Infect Dis* 1993;167:1053-8. doi:10.1093/infdis/167.5.1053 PMID:8387561
- Ompusunggu S, Hills SL, Maha MS, Moniaga VA, Susilarini NK, Widjaya A et al. Confirmation of Japanese encephalitis as an endemic human disease through sentinel surveillance in Indonesia. *Am J Trop Med Hyg* 2008;79:963-70. PMID:19052312
- Fischer M, Hills S, Staples E, Johnson B, Yaich M, Solomon T. Japanese encephalitis prevention and control: advances, challenges, and new initiatives. In: Scheld WM, Hammer SM, Hughes JM, editors. *Emerging infections 8*. Washington: ASM Press; 2008. pp. 93-124.

9. World Health Organization. Japanese encephalitis vaccines. *Wkly Epidemiol Rec* 2006;81:331–40. PMID:16933380
10. Solomon T. Control of Japanese encephalitis—within our grasp? *N Engl J Med* 2006;355:869–71. doi:10.1056/NEJMp058263 PMID:16943399
11. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. *Emerg Infect Dis* 2009;15:1–7. doi:10.3201/eid1501.080311 PMID:19116041
12. Konishi E, Kitai Y, Tabei Y, Nishimura K, Harada S. Natural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program. *Vaccine* 2010;28:2664–70. doi:10.1016/j.vaccine.2010.01.008 PMID:20080072
13. Xufang Y, Huanyu W, Shihong F, Xiaoyan G, Shuye Z, Chunting L et al. Etiological spectrum of clinically diagnosed Japanese encephalitis cases reported in Guizhou Province, China, in 2006. *J Clin Microbiol* 2010;48:1343–9. doi:10.1128/JCM.01009-09 PMID:20147638
14. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. *Vaccine* 2000;18(Suppl 2):1–25. doi:10.1016/S0264-410X(00)00037-2 PMID:10821969
15. Fischer M, Griggs A, Staples JE. Japanese encephalitis (JE). In: Centers for Disease Control and Prevention. *CDC health information for international travel 2010*. Atlanta: US Department of Health and Human Services, US Public Health Service; 2009.
16. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 1993;42(RR-1):1–15. PMID:8381504
17. Report on the: *Third Biregional Meeting on Control of Japanese Encephalitis, Ho Chi Minh City, Viet Nam, 26–27 April 2007*. Manila: World Health Organization; 2007.
18. Infectious Disease Surveillance Center, National Institute for Infectious Diseases. Japanese encephalitis, Japan, 2003–2008. *Infect Agents Surveil Rep* 2009;30:147–8.
19. *PATH's Japanese encephalitis project: collaboration and commitment to protect Asia's children*. Seattle: Program for Appropriate Technology in Health; 2009. Available from: http://www.path.org/files/VAD_je_rpt.pdf [accessed 17 July 2011].
20. Yin Z, Wang H, Yang J, Luo H, Li Y, Hadler SC et al.; Acute Meningitis and Encephalitis Syndrome (AMES) Study Group. Japanese encephalitis disease burden and clinical features of Japanese encephalitis in four cities in the People's Republic of China. *Am J Trop Med Hyg* 2010;83:766–73. doi:10.4269/ajtmh.2010.09-0748 PMID:20889863
21. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ* 2004;82:346–53. PMID:15298225
22. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097. doi:10.1371/journal.pmed.1000097 PMID:19621072
23. Arai S, Matsunaga Y, Takasaki T, Tanaka-Taya K, Taniguchi K, Okabe N et al.; Vaccine Preventable Diseases Surveillance Program of Japan. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. *Jpn J Infect Dis* 2008;61:333–8. PMID:18806337
24. Hashimoto S, Kawado M, Murakami Y, Izumida M, Ohta A, Tada Y et al. Epidemics of vector-borne diseases observed in infectious disease surveillance in Japan, 2000–2005. *J Epidemiol* 2007;17(Suppl 1):S48–55. doi:10.2188/jea.17.S48 PMID:18239342
25. Touch S, Hills S, Sokhal B, Sammang C, Sovann L, Khieu V et al. Epidemiology and burden of disease from Japanese encephalitis in Cambodia: results from two years of sentinel surveillance. *Trop Med Int Health* 2009;14:1365–1373. doi:10.1111/j.1365-3156.2009.02380.x PMID:19814760
26. Kari K, Liu W, Gautama K, Mammen MP Jr, Clemens JD, Nisalak A et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. *BMC Med* 2006;4:8. doi:10.1186/1741-7015-4-8 PMID:16603053
27. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL et al. Protection against Japanese encephalitis by inactivated vaccines. *N Engl J Med* 1988;319:608–14. doi:10.1056/NEJM198809083191004 PMID:2842677
28. Partridge J, Ghimire P, Sedai T, Bista MB, Banerjee M. Endemic Japanese encephalitis in the Kathmandu valley, Nepal. *Am J Trop Med Hyg* 2007;77:1146–9. PMID:18165538
29. Wierzbica TF, Ghimire P, Malla S, Banerjee MK, Shrestha S, Khanal B et al. Laboratory-based Japanese encephalitis surveillance in Nepal and the implications for a national immunization strategy. *Am J Trop Med Hyg* 2008;78:1002–6. PMID:18541784
30. Paul RC, Rahman M, Gurley ES, Hossain MJ, Diorditsa S, Hasan M et al. A novel low-cost approach to estimate the incidence of Japanese encephalitis in the catchment area of three hospitals in Bangladesh. *Am J Trop Med Hyg* Forthcoming.
31. Bhattachan A, Amatya S, Sedai TR, Upreti SR, Partridge J. Japanese encephalitis in hill and mountain districts, Nepal. *Emerg Infect Dis* 2009;15:1691–2. PMID:19861079
32. Wong SC, Ooi MH, Abdullah AR, Wong SY, Krishnan S, Tio PH et al. A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997–2006. *Trop Med Int Health* 2008;13:52–5. doi:10.1111/j.1365-3156.2007.01967.x PMID:18291002
33. *World population prospects, 2010 revision* [Internet]. New York: United Nations; 2010. Available from: <http://esa.un.org/unpd/wpp/index.htm> [accessed 17 July 2011].
34. *The world factbook*. Langley: Central Intelligence Agency; 2011. Available from: <https://www.cia.gov/library/publications/the-world-factbook/index.html> [accessed 17 July 2011].
35. Okuno T. An epidemiological review of Japanese encephalitis. *World Health Stat Q* 1978;31:120–33. PMID:214963
36. Immunization surveillance, assessment and monitoring: reported cases of Japanese encephalitis, 2006–2009 [Internet]. Geneva: World Health Organization; 2010. Available from: http://www.who.int/immunization_monitoring/en/globalsummary/timeseries/tsincidencejap.htm [accessed 17 July 2011].
37. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. *PLoS Negl Trop Dis* 2007;1:e114. doi:10.1371/journal.pntd.0000114 PMID:18060077
38. Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. *Bull World Health Organ* 2003;81:334–42. PMID:12856051
39. Maha MS, Moniaga VA, Hills SL, Widjaya A, Sasmito A, Hariati R et al. Outcome and extent of disability following Japanese encephalitis in Indonesian children. *Int J Infect Dis* 2009;13:e389–93. doi:10.1016/j.ijid.2009.01.009 PMID:19346144
40. Ding D, Hong Z, Zhao SJ, Clemens JD, Zhou B, Wang B et al. Long-term disability from acute childhood Japanese encephalitis in Shanghai, China. *Am J Trop Med Hyg* 2007;77:528–33. PMID:17827373
41. Ooi MH, Lewthwaite P, Lai BF, Mohan A, Clear D, Lim L et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central sarawak, malaysia, 1997–2005. *Clin Infect Dis* 2008;47:458–68. doi:10.1086/590008 PMID:18616397
42. Hills SL, Van Cuong N, Touch S, Mai HH, Soeung SC, Lien TT et al. Disability from Japanese encephalitis in Cambodia and Viet Nam. *J Trop Pediatr* 2010. In press doi:10.1093/tropej/fmp133 PMID:20068031
43. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. *Lancet* 2009;374:903–11. doi:10.1016/S0140-6736(09)61203-4 PMID:19748399
44. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. *Lancet* 2009;374:893–902. doi:10.1016/S0140-6736(09)61204-6 PMID:19748398
45. Li YX, Li MH, Fu SH, Chen WX, Liu QY, Zhang HL et al. Japanese encephalitis, Tibet, China. *Emerg Infect Dis* 2011;17:934–6. PMID:21529419

Table 1. Japanese encephalitis (JE) incidence group, endemic areas, current vaccine programme description (as of 2009) and population data, by country

IG	Description	Country	Endemic area(s)	Vaccination programme	Year	Population, endemic area(s) only			
						Data type	Total (millions)	Age (years) 0–14 ≥ 15	
A	Historically high-incidence areas with long-standing, high-quality vaccination programmes	China (Taiwan)	Countrywide	Mass vaccination of children was begun in 1968, followed by routine childhood vaccination	2010	Inter-census estimate	23.1	3.6	19.5
		Japan	Countrywide	Vaccine first introduced in 1954; widespread childhood vaccination conducted from 1967 to 2004; recommendation for vaccination withdrawn in 2005 and coverage declined; recommendation reinstated in 2009, but coverage remains low	2010	Census	128.1	17.2	110.9
B	Extremely low-incidence areas: rare human cases; minimal or no vaccination programmes	Republic of Korea	Countrywide	Routine childhood vaccination programme began in the 1970s	2005	Census	47.3	7.8	39.5
		Australia	Torres Strait Islands and Far North Statistical Division, Queensland State	Mass vaccination was conducted on outer Torres Straits Islands only in 1995, followed by routine vaccination programme	2009	Inter-census estimate	0.25	0.05	0.2
C1	Historically high-incidence areas with expanding vaccination programmes	India	Lowest-incidence stratum (north-west –Haryana, Punjab)	Generally none, but mass-vaccination campaigns conducted in a portion of Haryana state in 2007–2009	2008	Inter-census estimate	53.1	16.2	36.8
		Pakistan	Sindh province	None	1998	Census	30.4	10.8	19.7
		Russian Federation	Primorsky Krai	None	2010	Census	2.0	0.3	1.7
		Singapore	Countrywide	None	2010	Census	3.8	0.7	3.1
C2	Historically high-incidence areas with expanding vaccination programmes	China	Higher-incidence stratum (Anhui, Chongqing, Fujian, Gansu, Guangdong, Guangxi, Guizhou, Henan, Hubei, Hunan, Jiangsu, Jiangxi, Shaanxi, Shandong, Shanxi, Sichuan, Yunnan, and Zhejiang provinces)	From 1981 to 2007, vaccine used extensively but non-uniformly in children; beginning in 2008, incorporated into Expanded Programme on Immunization in all endemic provinces	2010	Census	1025.7	200.0	825.7
		China	Lower-incidence stratum (Beijing, Hainan, Hebei, Heilongjiang, Jilin, Liaoning, Nei Mongol, Ningxia, Shanghai, and Tianjin provinces; Hong Kong Special Administrative Region and Macau Special Administrative Region)	As above, except for Hong Kong SAR and Macau SAR, which have no vaccination programmes	2007	Inter-census estimate	276.6	53.9	222.7

IG	Description	Country	Endemic area(s)	Vaccination programme	Year	Population, endemic area(s) only			
						Data type	Total (millions)	Age (years)	
								0–14	≥ 15
D	High-incidence areas with nascent or no vaccination programmes	Cambodia	Countrywide	National programme started in three provinces in late 2009	2008	Census	13.4	4.3	9.1
		Indonesia	Higher-incidence stratum (Bali, Nusa Tenggara, all provinces on Borneo and Sulawesi, and the Moluccas)	None	2010	Census	50.4	13.6	36.8
		Lao People's Democratic Republic	Countrywide	None	2009	Inter-census estimate	6.1	2.1	4.0
		Malaysia	Sabah and Labuan (all of Malaysian Borneo except Sarawak)	None	2000	Census	3.2	1.0	2.2
		Myanmar	Countrywide	None	2000	Inter-census estimate	49.0	12.5	36.5
		Philippines	Countrywide	None	2007	Census	88.6	31.4	57.2
		Timor-Leste	Countrywide	None	2010	Census	1.1	0.5	0.6
		Indonesia	Lower-incidence stratum (all provinces on Sumatra, Java and Papua, plus Kepulauan Bangka Belitung and Riau)	None	2005	Inter-census estimate	187.2	50.5	136.6
		Malaysia	Peninsular Malaysia	None	2000	Census	21.9	6.6	15.3
		Papua New Guinea	All provinces on the main island	None	2000	Census	4.4	1.7	2.7
E	Medium-incidence areas with no vaccination programmes	India	Highest-incidence stratum (north-central and north-eastern – Assam, Bangla [West Bengal], Bihar, Manipur, Uttar Pradesh)	National programme started in 2006; previously, very limited state-based use as outbreak response	2008	Inter-census estimate	428.6	131.2	297.5
		Nepal	Higher-incidence stratum (24 Terai and Inner Terai districts)	Vaccine introduced in 2006	2001	Census	12.5	4.5	8.0
		Bangladesh	Countrywide	None	2001	Census	124.4	38.9	85.4
		Bhutan	Southern foothills (Chhukha, Dagana, Monggar, Pemagatshel, Samdrupjongkhar, Samtse, Sarpang, Trashigang, Tsirang, Zhenbang districts)	None	2005	Census	0.4	0.1	0.3
F	Historically high-incidence areas with expanding vaccination programmes	Brunei Darussalam	Countrywide	None	2010	Census	0.4	0.1	0.3
		Nepal	Lower-incidence stratum (51 mountain and hill districts)	Vaccine campaigns conducted in three hill districts in 2008–2009	2001	Census	10.7	3.9	6.8
G	Low-incidence areas with minimal or no vaccination programmes								

IG	Description	Country	Endemic area(s)	Vaccination programme	Year	Population, endemic area(s) only			
						Data type	Total (millions)	Age (years) 0–14 ≥ 15	
H	Historically medium-to-high-incidence areas with expanding vaccination programmes	India Malaysia	Medium-incidence stratum (south – Andhra Pradesh, Goa, Kerala, Karnataka, Maharashtra, Pondicherry, Tamil Nadu) Sarawak	National programme started in 2006; previously, very limited state-based use as outbreak response Vaccine introduced in 2001 nationwide, but subsequently scaled-back to Sarawak only	2008	Inter-census estimate	366.4	112.1	254.3
		Sri Lanka	Countrywide	Vaccine introduced in 1988, with initial use in high-risk areas	2010	Inter-census estimate	20.7	5.1	15.5
		Thailand	Countrywide	Routine childhood vaccination began in 1990, initially in higher-risk provinces	2006	Inter-census estimate	62.8	12.9	49.9
		Viet Nam	Countrywide	Vaccine introduced in 1997, with initial use in high-risk areas	2009	Census	85.8	20.3	65.6
I	Historically medium-to-high-incidence area with expanding vaccination programme	Democratic People's Republic of Korea	All provinces except Ryanggang and North Hamyong	Minimal vaccine coverage from 1994 to 2008; in 2009, a mass campaign vaccinated nearly half a million children in five provinces and Pyongyang	2008	Census	20.3	4.6	15.7
			Subtotal (JE-endemic areas only)^a				3150.9	769.2	2381.7

IG, incidence group.

^a The total population (endemic + non-endemic areas) aged 0–14 years is 1000.9 million, aged 15+ years is 2692.7 million, and combined is 3693.6 million (country-specific data not shown).

Table 2. Summary of the 12 primary references used to estimate the incidence of Japanese encephalitis (JE) in Asia, by incidence group

IG	Country	Reference	Study type	Laboratory-confirmed		Study period	Study area	Study age group	Estimated study population	Estimated annual incidence ^a	Relative quality of study data
				No.	%						
A	Japan	Arai et al. (2008) ²³	Routine (passive) national surveillance	53	100	1992–2004 (13 years)	Entire country	All	126.4 million (approx. mid-interval population)	0.003	Medium-quality data from national surveillance system based on physician reports of laboratory-confirmed cases; caveats include that laboratory methods used have evolved over time.
		Hashimoto et al. (2007) ²⁴	Routine (passive) national surveillance	33	100	2000–2005 (6 years)	Entire country	All	126.55 million	0.004	Medium-quality data from national surveillance, based on laboratory confirmation of physician-reported, clinically suspected cases.
C1	China	Yin et al. (2010) ²⁰	Multiple hospital-based surveillance	121	100	Apr. 2007 to Sept. 2008 (17 months) or Sept. 2006 to Sept. 2008 (25 months), depending on prefecture	Guigang prefecture, Guangxi province; Yichang prefecture, Hubei province; Jinan prefecture, Shandong province	All	14.13 million	0.6 ^b	Medium-quality data from 6 carefully selected sentinel hospitals in each prefecture; caveats include that not all hospitals in each prefecture were included.
		Xufang et al. (2010) ¹³	Multiple hospital-based surveillance	1609	75	2006 (1 year) ^c	Guizhou province	All	37.6 million	4.3	Medium-quality data; all hospitals in the province were included in surveillance, but samples were unavailable for testing in 25% (455/1837) of clinically suspected cases, so incidence estimate was adjusted upward, based on seropositivity rate among those tested.
C2	China	Yin et al. (2010) ²⁰	Multiple hospital-based surveillance	18	100	Apr. 2007 to Sept. 2008 (17 months)	Shijiazhuang prefecture, Hebei province	All	5.06 million	0.01 ^d	See above.
D	Cambodia	Touch et al. (2009) ²⁵	Multiple hospital-based surveillance	583 ^e	19	2007 (1 year)	Entire country	0–14 years	5.25 million	11.1	Medium-quality data from 6 carefully selected sentinel hospitals distributed throughout the country.
	Indonesia	Kari et al. (2006) ²⁶	Multiple hospital- and clinic-based enhanced (active) surveillance	90	100	July 2001 to Dec. 2003 (2.5 years)	Bali province	0–11 years	599 120	6.0	High-quality data; all health care facilities in the province providing care for the study population were included in active surveillance system.
	Thailand	Hoke et al. (1988) ^{27,f}	Vaccine trial; enhanced (active) local public health surveillance	11	100	1985–1986 (2 years)	Kamphangphet province	1–14 years	21 516	25.6	High-quality data; all health care facilities in the province providing care for the study population were included in active surveillance system.

IG	Country	Reference	Study type	Laboratory-confirmed		Study period	Study area	Study age group	Estimated study population	Estimated annual incidence ^a	Relative quality of study data
				No.	%						
F	Nepal	Partridge et al. (2007) ²⁸	Multiple hospital-based surveillance	225	(100)	2006 (1 year)	Terai & Inner Terai districts (<i>n</i> =24)	All	12.46 million ^g	1.8	Medium-quality data from national surveillance system, based on laboratory confirmation of clinically suspected cases using an incomplete network of 93 hospitals and clinics; caveats include that specimens for laboratory testing were unavailable in 16% of clinically suspected cases, with no adjustment for this potential source of underdiagnosis.
		Wierzbak et al. (2008) ²⁹	Multiple hospital-based surveillance	951	100	May 2004 to Apr. 2006 (2 years)	Terai & Inner Terai districts (<i>n</i> =24)	All	12.46 million ^g	3.8	Medium-quality data from national surveillance system, based on laboratory confirmation of clinically suspected cases using an incomplete network of 64 hospitals; caveats include that specimens for laboratory testing were unavailable in 31% of clinically suspected cases, with no adjustment for this potential source of underdiagnosis.
G	Bangladesh	Paul et al. (in press) ³⁰	Multiple hospital-based surveillance	472 ^d	8	Oct. 2007 to Dec. 2008 (15 months)	Bagerhat, Chittagong, Cox's Bazar, Jessore, Jhenaidah, Khulna, Naogaon, Narail, Nawabganj, Rajshahi, & Satkhira districts	All	27.5 million	1.4 ^d	Relatively lower quality data because incidence was not directly measured, but rather extrapolated retrospectively from hospitalized, laboratory-confirmed cases to non-hospitalized, clinically suspected but laboratory-untested patients.
	Nepal	Partridge et al. (2007) ²⁸	Multiple hospital-based surveillance	67	100	2006 (1 year)	Mountain and hill (non-Terai) districts (<i>n</i> =51)	All	10.69 million ^g	0.6	See above.
		Wierzbak et al. (2008) ²⁹	Multiple hospital-based surveillance	84	100	May 2004 to Apr. 2006 (2 years)	Mountain and hill (non-Terai) districts (<i>n</i> =51)	All	10.69 million ^g	0.4	See above.
		Bhattachan et al. (2009) ³¹	Multiple hospital-based surveillance	90	100	2007 (1 year)	Mountain and hill (non-Terai) districts (<i>n</i> =51)	All	10.69 million ^g	0.8	Medium-quality data from national surveillance system, based on laboratory confirmation of clinically suspected cases using an incomplete network of hospitals; specimens for laboratory testing were available in 96% of clinically suspected cases.
H	Malaysia	Wong et al. (2008) ³²	Single hospital-based surveillance	49	100	July 2001–2006 (post-vaccine programme) (5.5 years)	Sibu Hospital, Sarawak state	All	600 000 (in catchment area)	1.5	Medium-quality data from a single, central, large, sentinel hospital; caveats include that incidence estimates were apparently based on the assumption that 100% of JE cases in this hospital's catchment area would present to this hospital, and that none from outside the catchment area would do so.

IG, incidence group.

^a Per 100 000.^b Weighted average of results from all three prefectures (using raw incidence data, as data used in their adjustment of incidence rates were not provided).^c April to November, but because this timeframe brackets the JE transmission season in the region, 1 year was used.^d Using raw incidence data, as data used in their adjustment of incidence rates were not provided.^e 100% of study cases were laboratory-confirmed; the study's authors then extrapolated their results to a larger geographic area, proportionate to the total number of acute encephalitis syndrome cases reported.^f These historical, pre-vaccination-era data from Thailand were used, in part, to estimate incidence in Incidence Group D, but present-day Thailand was included in Incidence Group H.^g 2001 census data.